POZN, POZEN Inc.

** POZN presented data from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH. These data were presented for the first time at Digestive Disease Week (DDW) 2012 in San Diego, California at the San Diego Convention Center on May 19, 2012, at 9:15 a.m. (PT).

These data were presented for the first time at Digestive Disease Week (DDW) 2012 in San Diego, California at the San Diego Convention Center on May 19, 2012, at 9:15 a.m. (PT).

POZN is creating a portfolio of integrated aspirin therapies – the PA platform. The products in the PA portfolio are intended to significantly reduce GI ulcers and other GI complications compared to taking aspirin alone.

The first candidate is PA32540. It is a coordinated-delivery tablet combining immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin. This novel, patented product is administered orally once a day and will be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers.

POZN is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs.

More about POZN at www.pozen.com

***************

AMGN, Amgen Inc.

** AMGN reported updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE(R)) antibodies, designed to harness the body's cell-destroying T cells to kill cancer cells. Blinatumomab targets cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas, such as ALL.

Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The disease progresses rapidly and affects immature blood cells, rather than mature ones.

Full results of the study will be presented during an oral abstract session at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 4. (Abstract Number 6500; Oral Presentation, 8:00 a.m. - 8:15 a.m. CDT, E354a).

AMGN discovers, develops, manufactures and delivers innovative human therapeutics. AMGN have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses.

More about AMGN at www.amgen.com

***************

PRGO, Perrigo Co.

** PRGO reported that it has received final approval from the FDA for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun.

This new product for the U.S. store brand market is bioequivalent to Novartis' Prevacid(R) 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.

PRGO is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients. PRGO is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market.

More about PRGO at www.perrigo.com

***************

With the growth of information on the internet has growth the amount of time people spend on it, which has in turn generated a new market for internet advertising. Some of the wealthiest companies in the world have made sure that they get a piece of the internet marketing pie, and for a good reason.

Crown Equity Holdings Inc., (CRWE.OB) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

CRWE’s division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.

More about CRWE at www.crownequityholdings.com.

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.